The Swiss company said it will use the funding to accelerate commercialization of its blood-based calcification propensity test for kidney disease patients.
DiaSorin said that the acquisition gives it access to Luminex's multiplexing technology, tests, and instruments and strengthens its MDx product portfolio.
